StemCell Therapy

JUPITER, Fla., Jan. 23, 2012 /PRNewswire/
-- BioRestorative Therapies, Inc. (OTCQB: BRTX.PK^[1] -
News^[2])
("BRT") today announced that it will be presenting at the
Seventh International Conference on Cell Therapy for
Cardiovascular Disease. The event, being held at the New
York-Presbyterian Hospital/Columbia University Medical Center,
is a two-and-a-half-day conference dedicated to the evolving
field of cell-based therapies for the repair and regeneration
of cardiac and vascular disease.

Dr. Amit Patel, Director of Clinical Regenerative Medicine and
Tissue Engineering at the University of Utah and a member of
the BRT Scientific Advisory Board, will be presenting his
findings relating to brown fat stem cells and metabolic
disorders (one of BRT's stem cell initiatives). His talk,
entitled "Metabolic Syndrome: A Role For Cell Therapy,"
will be on Wednesday, January 25th at 1:50 PM.

Mark Weinreb, Chairman and CEO of BRT, has also been selected
to serve on an industry panel and will discuss BRT's
ThermoStem™ Program and the use of brown fat stem cells
as potential therapeutics.  The session will be held on
Thursday, January 26th from 3:15-4:15 PM.

BRT is involved in a research initiative focusing on the use of
Brown Fat stem cells to potentially treat metabolic disorders
and obesity that may lead to heart disease, diabetes,
hypertension, kidney disease and other diseases and disorders.

The Conference will take place January 25-27 at the Vivien and
Seymour Milstein Family Heart Center, Myrna L. Daniels
Auditorium, NYPH/Columbia University Medical Center, 173 Fort
Washington Avenue, First Floor, New York City.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical
center of excellence using cell and tissue protocols, primarily
involving a patient's own (autologous) adult stem cells
(non-embryonic), allowing patients to undergo cellular-based
treatments. In June 2011, the Company launched a technology
that involves the use of a brown fat cell-based
therapeutic/aesthetic program, known as the ThermoStem™
Program.  The ThermoStem™ Program will focus on
treatments for obesity, weight loss, diabetes, hypertension,
other metabolic disorders and cardiac deficiencies and will
involve the study of stem cells, several genes, proteins and/or
mechanisms that are related to these diseases and disorders. As
more and more cellular therapies become standard of care, the
Company believes its strength will be its focus on the unity of
medical and scientific explanations for clinical procedures and
outcomes for future personal medical applications.  The
Company also plans to offer and sell facial creams and products
under the Stem Pearls™ brand.

This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the
forward-looking statements as a result of various factors and
other risks, including those set forth in the Company's Form
10, as amended, filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in
this release are made as of the date hereof and the Company
undertakes no obligation to update such statements.

CONTACT:
Mark Weinreb
CEO
Tel: (561) 904-6070
Fax: (561) 429-5684

References

1. ^{^} BRTX.PK
   (finance.yahoo.com)
2. ^{^} News
   (finance.yahoo.com)